沙库巴曲缬沙坦对射血分数降低性心衰患者血浆去甲肾上腺素和血清心肌肌钙蛋白I水平的影响研究  

Effect of sacubitril/valsartan on plasma norepinephrine and serum cardiac troponin I levels in patients with heart failure with reduced ejection fraction

作　　者：羡微微 刘桂清 XIAN Weiwei;LIU Guiqing(Graduate Training Base of the First Affiliated Hospital of Qiqihar Medical College,Jinzhou Medical University,Qiqihar 161041)

机构地区：[1]锦州医科大学齐齐哈尔医学院附属第一医院研究生培养基地,齐齐哈尔161041 [2]齐齐哈尔医学院附属第一医院,齐齐哈尔161041

出　　处：《陕西医学杂志》2020年第10期1306-1309,共4页Shaanxi Medical Journal

摘　　要：目的:探究沙库巴曲缬沙坦对射血分数降低性心衰(HFREF)患者血浆去甲肾上腺素(NE)和血清心肌肌钙蛋白I(cTnI)水平的影响。方法:将56例HFREF患者纳入研究。将其以随机数字表法分为试验组(26例)和对照组(30例)。两组均予以常规抗心衰治疗。在此基础上对照组增用盐酸贝那普利治疗,试验组采用沙库巴曲缬沙坦治疗。对所有受试者均进行为期6个月的随访观察,比较治疗前以及治疗后1个月两组血浆NE以及血清cTnI水平,治疗前以及治疗后6个月的心功能指标变化情况,6个月内再次住院次数以及累计住院时间,不良反应发生情况。结果:治疗后试验组血浆NE与血清cTnI水平均低于对照组(均P<0.05)。治疗后试验组左室射血分数(LVEF)高于对照组,而左心房内径(LA)、左心室舒张末期内径(LVEDD)低于对照组(均P<0.05)。试验组住院次数以及累计住院时间均少于对照组(均P<0.05)。试验组及对照组在各项不良反应发生率方面对比差异无统计学意义(均P>0.05)。结论:沙库巴曲缬沙坦对HFREF患者血浆NE和血清cTnI水平均有显著的改善作用,同时有利于促进患者心功能的改善,降低不良反应发生风险,减少再次住院次数以及累计住院时间。Objective:To study the effect of sacubitril/valsartan on plasma norepinephrine(NE)and serum cardiac troponin I(cTnI)levels in patients with heart failure with reduced ejection fraction(HFREF).Methods:56 patients with HFREF were included in the study.They were divided into experimental group(26 cases)and control group(30 cases)by random number table method.Both groups received routine anti-heart failure treatment.On this basis,the control group was treated with benazepril hydrochloride,and the experimental group was treated with sacubitril/valsartan.All subjects were followed up for 6 months to compare the plasma NE and serum cTnI levels of the two groups before and 1 month after treatment,the changes in cardiac function indicators before and 6 months after treatment,the number of rehospitalization and the cumulative length of hospital stay within 6 months,and the incidence of adverse reactions.Results:After treatment,the serum levels of NE and cTnI in the experimental group were lower than those in the control group(All P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of the experimental group was higher than that of the control group,while the left atrial diameter(LA)and left ventricular end-diastolic diameter(LVEDD)were lower than those of the control group(all P<0.05).The hospitalization frequency and cumulative hospitalization time in the experimental group were lower than those in the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(all P>0.05).Conclusion:Sacubitril/valsartan can significantly improve the levels of plasma NE and serum cTnI in HFREF patients,and promote the improvement of cardiac function,and reduce the risk of adverse reactions,and reduce the number of rehospitalization and the cumulative length of hospital stay.

关 键 词：射血分数降低性心衰 沙库巴曲缬沙坦 去甲肾上腺素 心肌肌钙蛋白I 心脏不良事件 不良反应 

分 类 号：R541.6[医药卫生—心血管疾病]